JPRN-jRCTs071220048
Completed
Phase 1
Angiogenesis augmentation therapy for indirect revascularization of moyamoya disease using G-CSF - EDFAPS-G
Morioka Motohiro0 sites5 target enrollmentAugust 29, 2022
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Morioka Motohiro
- Enrollment
- 5
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Moyamoya disease requiring direct/indirect revascularization.
- •2\.Age:20\-60 years old.
- •3\.Obtain informed consent by the document.
Exclusion Criteria
- •1\.Splenomegaly or splenic lesions on abdominal echo.
- •2\.Leukocytosis more than 15000/mm3
- •3\.Past histries of symptomatic intracranial hemorrhage, bleeding tendency or coagulating disorders.
- •4\.Hyper reactivity to G\-CSF.
- •5\.Congestive heart failure or uncontrollable angina.
- •6\.Thrombocytopenia(less than 140000/mm3\)
- •7\.Liver dysfunction(AST(GOT),ALT(GPT) more than 100 IU/L)
- •8\.Renal dysfunction (creatinine 1\.5mg/dl and more)
- •9\.Difficult to continue this trial due to social problems, etc.
- •10\.Join other clinical trials.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Phase 2
Therapeutic neovascularization using intravenous adrenomedullin infusion for limb ischemiaJPRN-UMIN000003312First Department of Internal Medicine, Faculty of Medicine, University of Miyazaki10
Recruiting
Phase 4
Innovative endovascular treatment strategy by angiography, IVUS and pressure gradient guidance in SFA disease with a new nitinol stent system -A prospective multicenter studySymptomatic peripheral artery disease: -Moderate or severe claudication (Rutherford category 2 or 3) -Critical limb ischemia (Rutherford category 4 or 5)JPRN-UMIN000021844Japan Endovascular Treatment Conference300
Completed
Not Applicable
Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI Study)ISRCTN44258879niversity of Ottawa Heart Institute (Canada)170
Completed
Not Applicable
Angiogenic Therapy Against Peripheral Arterial Disease with bone marrow derived MSC grown in platelet-rich plasmaJPRN-UMIN000021426ational Center for Global Health and Medicine5
Unknown
Not Applicable
Multicenter trial of therapeutic angiogenesis in patients with intractable vasculitisJPRN-UMIN000000939Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine40